UB Paderborn / Katalog / Suche / in CDI

A New Scoring Method for Personalized Prognostic Prediction in Patients with Combined Hepatocellular and Cholangiocarcinoma After Surgery

Journal of gastrointestinal surgery, 2021-04, Vol.25 (4), p.971-982

2021

Volltextzugriff (PDF)

Sulfarotene Inhibits Colorectal Cancer via Mitigating Natural-Killer-Cell-Induced Stemness

Pharmaceuticals (Basel, Switzerland), 2024-03, Vol.17 (3), p.387

2024

Volltextzugriff (PDF)

The prognostic significance of microRNA-221 in hepatocellular carcinoma: An updated meta-analysis

The International journal of biological markers, 2021-08, Vol.36 (3), p.40-47

2021

Volltextzugriff (PDF)

IL-4/IL-4R axis signaling drives resistance to immunotherapy by inducing the upregulation of Fcγ receptor IIB in M2 macrophages

Cell death & disease, 2024-07, Vol.15 (7), p.500-15, Article 500

2024

Volltextzugriff (PDF)

JUNB mediates oxaliplatin resistance via the MAPK signaling pathway in gastric cancer by chromatin accessibility and transcriptomic analysis

Acta biochimica et biophysica Sinica, 2023-11, Vol.55 (11), p.1784-1796

2023

Volltextzugriff (PDF)

Prostate cancer-associated transcript 6 (PCAT6) promotes epithelial-mesenchymal transition and stemness and worsens prognosis in patients with colorectal cancer

Acta biochimica et biophysica Sinica, 2024-04, Vol.56 (6), p.866-878

2024

Volltextzugriff (PDF)

Negative correlation between acetyl-CoA acyltransferase 2 and cetuximab resistance in colorectal cancer

Acta biochimica et biophysica Sinica, 2023-06, Vol.55 (9), p.1467-1478

2023

Volltextzugriff (PDF)

ScRNA-seq of gastric cancer tissues reveals differences in the immune microenvironment of primary tumors and metastases

Oncogene, 2024-05, Vol.43 (20), p.1549-1564

2024

Volltextzugriff (PDF)

Oxaliplatin-Resistant Hepatocellular Carcinoma Drives Immune Evasion Through PD-L1 Up-Regulation and PMN-Singular Recruitment

Cellular and molecular gastroenterology and hepatology, 2023-01, Vol.15 (3), p.573-591

2023

Volltextzugriff (PDF)

Negative correlation between acetyl-CoA acyltransferase 2 and cetuximab resistance in colorectal cancer: Correlation between ACAA2 and cetuximab resistance in CRC

Acta biochimica et biophysica Sinica, 2023-06, Vol.55 (9), p.1467-1478

2023

Volltextzugriff (PDF)

Albumin-to-Alkaline Phosphatase Ratio is an Independent Prognostic Indicator in Combined Hepatocellular and Cholangiocarcinoma

Journal of Cancer, 2020-01, Vol.11 (17), p.5177-5186

2020

Volltextzugriff (PDF)

Prostate cancer-associated transcript 6 (PCAT6) promotes epithelial-mesenchymal transition and stemness and worsens prognosis in patients with colorectal cancer: PCAT6 promotes CRC metastasis

Acta biochimica et biophysica Sinica, 2024-04, Vol.56 (6), p.866-878

2024

Volltextzugriff (PDF)

Oxaliplatin-Resistant Hepatocellular Carcinoma Drives Immune Evasion Through PD-L1 Up-Regulation and PMN-Singular RecruitmentSummary

Cellular and molecular gastroenterology and hepatology, 2023-01, Vol.15 (3), p.573-591

2023

Volltextzugriff (PDF)

Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment

Annals of translational medicine, 2021-02, Vol.9 (3), p.237-237

2021

Volltextzugriff (PDF)

A Novel Pre-treatment Model Predicting Risk of Developing Refractoriness to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma

Journal of Cancer, 2020-01, Vol.11 (15), p.4589-4596

2020

Volltextzugriff (PDF)

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study

Journal of hematology and oncology, 2020-05, Vol.13 (1), p.48-12, Article 48

2020

Volltextzugriff (PDF)

Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

Clinical cancer research, 2020-08, Vol.26 (16), p.4216-4224

2020

Volltextzugriff (PDF)

Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials

Journal of hematology and oncology, 2021-10, Vol.14 (1), p.1-167, Article 167

2021

Volltextzugriff (PDF)

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

Blood, 2022-05, Vol.139 (21), p.3148-3158

2022

Volltextzugriff (PDF)

The architecture of silk-secreting organs during the final larval stage of silkworms revealed by single-nucleus and spatial transcriptomics

Cell reports (Cambridge), 2024-07, Vol.43 (7), p.114460, Article 114460

2024

Volltextzugriff (PDF)

Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer

Experimental hematology & oncology, 2022-09, Vol.11 (1), p.1-59, Article 59

2022

Volltextzugriff (PDF)

Impact of second forward-view examination on adenoma detection rate during unsedated colonoscopy: a randomized controlled trial

BMC gastroenterology, 2021-05, Vol.21 (1), p.213-213, Article 213

2021

Volltextzugriff (PDF)

Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201)

Frontiers in oncology, 2022-07, Vol.12, p.925236-925236

2022

Volltextzugriff (PDF)

Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi‐center, single‐arm, open‐label, phase 2 study

American journal of hematology, 2023-04, Vol.98 (4), p.571-579

2023

Volltextzugriff (PDF)

The clinical study of anti-BCMA CAR-T with single-domain antibody as antigen binding domain

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.8025-8025

2021

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

A New Scoring Method for Personalized Prognostic Prediction in Patients with Combined Hepatocellular and Cholangiocarcinoma After Surgery

Sulfarotene Inhibits Colorectal Cancer via Mitigating Natural-Killer-Cell-Induced Stemness

The prognostic significance of microRNA-221 in hepatocellular carcinoma: An updated meta-analysis

IL-4/IL-4R axis signaling drives resistance to immunotherapy by inducing the upregulation of Fcγ receptor IIB in M2 macrophages

JUNB mediates oxaliplatin resistance via the MAPK signaling pathway in gastric cancer by chromatin accessibility and transcriptomic analysis

Prostate cancer-associated transcript 6 (PCAT6) promotes epithelial-mesenchymal transition and stemness and worsens prognosis in patients with colorectal cancer

Negative correlation between acetyl-CoA acyltransferase 2 and cetuximab resistance in colorectal cancer

ScRNA-seq of gastric cancer tissues reveals differences in the immune microenvironment of primary tumors and metastases

Oxaliplatin-Resistant Hepatocellular Carcinoma Drives Immune Evasion Through PD-L1 Up-Regulation and PMN-Singular Recruitment

Negative correlation between acetyl-CoA acyltransferase 2 and cetuximab resistance in colorectal cancer: Correlation between ACAA2 and cetuximab resistance in CRC

Albumin-to-Alkaline Phosphatase Ratio is an Independent Prognostic Indicator in Combined Hepatocellular and Cholangiocarcinoma

Prostate cancer-associated transcript 6 (PCAT6) promotes epithelial-mesenchymal transition and stemness and worsens prognosis in patients with colorectal cancer: PCAT6 promotes CRC metastasis

Oxaliplatin-Resistant Hepatocellular Carcinoma Drives Immune Evasion Through PD-L1 Up-Regulation and PMN-Singular RecruitmentSummary

Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment

A Novel Pre-treatment Model Predicting Risk of Developing Refractoriness to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study

Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

The architecture of silk-secreting organs during the final larval stage of silkworms revealed by single-nucleus and spatial transcriptomics

Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer

Impact of second forward-view examination on adenoma detection rate during unsedated colonoscopy: a randomized controlled trial

Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201)

Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi‐center, single‐arm, open‐label, phase 2 study

The clinical study of anti-BCMA CAR-T with single-domain antibody as antigen binding domain

Suchergebnisse filtern